Optical Imaging of Cellular Immunotherapy against Prostate Cancer
The purpose of this study was to track fluorophore-labeled, tumor-targeted natural killer (NK) cells to human prostate cancer xenografts with optical imaging (OI). NK-92-scFv(MOC31)-zeta cells targeted to the epithelial cell adhesion molecule (EpCAM) antigen on prostate cancer cells and nontargeted...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2009-01-01
|
| Series: | Molecular Imaging |
| Online Access: | https://doi.org/10.2310/7290.2009.00002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561869820624896 |
|---|---|
| author | Sidhartha Tavri Priyanka Jha Reinhard Meier Tobias D. Henning Tina Müller Daniel Hostetter Christiane Knopp Magnus Johansson Verena Reinhart Sophie Boddington Akhilesh Sista Winfried S. Wels Heike E. Daldrup-Link |
| author_facet | Sidhartha Tavri Priyanka Jha Reinhard Meier Tobias D. Henning Tina Müller Daniel Hostetter Christiane Knopp Magnus Johansson Verena Reinhart Sophie Boddington Akhilesh Sista Winfried S. Wels Heike E. Daldrup-Link |
| author_sort | Sidhartha Tavri |
| collection | DOAJ |
| description | The purpose of this study was to track fluorophore-labeled, tumor-targeted natural killer (NK) cells to human prostate cancer xenografts with optical imaging (OI). NK-92-scFv(MOC31)-zeta cells targeted to the epithelial cell adhesion molecule (EpCAM) antigen on prostate cancer cells and nontargeted NK-92 parental cells were labeled with the near-infrared dye DiD (1,1-dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine). The fluorescence, viability, and cytotoxicity of the labeled cells were evaluated. Subsequently, 12 athymic rats with prostate cancer xenografts underwent OI scans before and up to 24 hours postinjection of DiD-labeled parental NK-92 cells or NK-92-scFv(MOC31)-zeta cells. The tumor fluorescence intensity was measured and compared between pre- and postinjection scans and between both groups using t -tests. OI data were confirmed with fluorescence microscopy. In vitro studies demonstrated a significant increase in the fluorescence of labeled cells compared with unlabeled controls, which persisted over a period of 24 hours without any significant change in the viability. In vivo studies demonstrated a significant increase in tumor fluorescence at 24 hours postinjection of tumor-targeted NK-92-scFv(MOC31)-zeta cells but not parental NK cells. Ex vivo OI scans and fluorescence microscopy confirmed a specific accumulation of NK-92-scFv(MOC31)-zeta cells but not parental NK cells in the tumors. Tumor-targeted NK-92-scFv(MOC31)-zeta cells could be tracked to prostate cancer xenografts with OI. |
| format | Article |
| id | doaj-art-980627d9af1447669b868f221dbb9b2e |
| institution | Kabale University |
| issn | 1536-0121 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Molecular Imaging |
| spelling | doaj-art-980627d9af1447669b868f221dbb9b2e2025-01-03T01:20:02ZengSAGE PublishingMolecular Imaging1536-01212009-01-01810.2310/7290.2009.0000210.2310_7290.2009.00002Optical Imaging of Cellular Immunotherapy against Prostate CancerSidhartha TavriPriyanka JhaReinhard MeierTobias D. HenningTina MüllerDaniel HostetterChristiane KnoppMagnus JohanssonVerena ReinhartSophie BoddingtonAkhilesh SistaWinfried S. WelsHeike E. Daldrup-LinkThe purpose of this study was to track fluorophore-labeled, tumor-targeted natural killer (NK) cells to human prostate cancer xenografts with optical imaging (OI). NK-92-scFv(MOC31)-zeta cells targeted to the epithelial cell adhesion molecule (EpCAM) antigen on prostate cancer cells and nontargeted NK-92 parental cells were labeled with the near-infrared dye DiD (1,1-dioctadecyl-3,3,3,3-tetramethylindodicarbocyanine). The fluorescence, viability, and cytotoxicity of the labeled cells were evaluated. Subsequently, 12 athymic rats with prostate cancer xenografts underwent OI scans before and up to 24 hours postinjection of DiD-labeled parental NK-92 cells or NK-92-scFv(MOC31)-zeta cells. The tumor fluorescence intensity was measured and compared between pre- and postinjection scans and between both groups using t -tests. OI data were confirmed with fluorescence microscopy. In vitro studies demonstrated a significant increase in the fluorescence of labeled cells compared with unlabeled controls, which persisted over a period of 24 hours without any significant change in the viability. In vivo studies demonstrated a significant increase in tumor fluorescence at 24 hours postinjection of tumor-targeted NK-92-scFv(MOC31)-zeta cells but not parental NK cells. Ex vivo OI scans and fluorescence microscopy confirmed a specific accumulation of NK-92-scFv(MOC31)-zeta cells but not parental NK cells in the tumors. Tumor-targeted NK-92-scFv(MOC31)-zeta cells could be tracked to prostate cancer xenografts with OI.https://doi.org/10.2310/7290.2009.00002 |
| spellingShingle | Sidhartha Tavri Priyanka Jha Reinhard Meier Tobias D. Henning Tina Müller Daniel Hostetter Christiane Knopp Magnus Johansson Verena Reinhart Sophie Boddington Akhilesh Sista Winfried S. Wels Heike E. Daldrup-Link Optical Imaging of Cellular Immunotherapy against Prostate Cancer Molecular Imaging |
| title | Optical Imaging of Cellular Immunotherapy against Prostate Cancer |
| title_full | Optical Imaging of Cellular Immunotherapy against Prostate Cancer |
| title_fullStr | Optical Imaging of Cellular Immunotherapy against Prostate Cancer |
| title_full_unstemmed | Optical Imaging of Cellular Immunotherapy against Prostate Cancer |
| title_short | Optical Imaging of Cellular Immunotherapy against Prostate Cancer |
| title_sort | optical imaging of cellular immunotherapy against prostate cancer |
| url | https://doi.org/10.2310/7290.2009.00002 |
| work_keys_str_mv | AT sidharthatavri opticalimagingofcellularimmunotherapyagainstprostatecancer AT priyankajha opticalimagingofcellularimmunotherapyagainstprostatecancer AT reinhardmeier opticalimagingofcellularimmunotherapyagainstprostatecancer AT tobiasdhenning opticalimagingofcellularimmunotherapyagainstprostatecancer AT tinamuller opticalimagingofcellularimmunotherapyagainstprostatecancer AT danielhostetter opticalimagingofcellularimmunotherapyagainstprostatecancer AT christianeknopp opticalimagingofcellularimmunotherapyagainstprostatecancer AT magnusjohansson opticalimagingofcellularimmunotherapyagainstprostatecancer AT verenareinhart opticalimagingofcellularimmunotherapyagainstprostatecancer AT sophieboddington opticalimagingofcellularimmunotherapyagainstprostatecancer AT akhileshsista opticalimagingofcellularimmunotherapyagainstprostatecancer AT winfriedswels opticalimagingofcellularimmunotherapyagainstprostatecancer AT heikeedaldruplink opticalimagingofcellularimmunotherapyagainstprostatecancer |